Market Cap 20.68M
Revenue (ttm) 320,000.00
Net Income (ttm) -11.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,509.37%
Debt to Equity Ratio 0.21
Volume 71,600
Avg Vol 211,936
Day's Range N/A - N/A
Shares Out 15.91M
Stochastic %K 21%
Beta 0.52
Analysts Sell
Price Target $10.25

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 401 426 4664
Address:
123 E. Tarpon Ave., Tarpon Springs, United States
biotrade123
biotrade123 Jun. 29 at 7:23 PM
$ALLR apparently the proposal to dilute was passed, Google AI bottomline: The Bottom Line The shareholder meeting confirms that ALLR is a trading utility, not a long-term fundamental investment. The institutional machinery is now fully authorized to keep the company listed and alive, using retail liquidity as its primary capitalization engine. The smart strategy here is to avoid getting caught up in retail board hype during a PR pump—instead, treat the $1.15 to $1.25 zone as a high-probability accumulation bounce pocket, and ruthlessly lock in profits anywhere near $1.55 to $1.70 before the automated Tumim dilution machine can grind the momentum back down.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 5:03 PM
$SLS sold 1K shares to buy more $ALLR $CGTX and $TNXP 🏦 💊 🧠 💤
2 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 3:56 PM
$KPTI lol Ipsen bought Kartos and not Karyopharm? How come CEO Richard Paulson and Karyopharm’s BD team couldn’t get that deal? Uncle Rolli and I could tell you why… we are focused on fixing biotechs, not just selling them on the cheap because private companies are often more poorly run than publicly traded ones. 🏦 $SLS $CCCC and $ALLR ALL DAY over the Krazy Pharm of Newton Massachusetts 😂
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 29 at 1:17 PM
$ALLR https://www.biospace.com/drug-development/4-ovarian-cancer-candidates-to-watch-gsk-allarity-and-more
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 27 at 5:22 AM
$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔
0 · Reply
Wody
Wody Jun. 26 at 7:27 PM
$ALLR how big is the drop gonna be AH and Monday?! Hope we start heading the other direction…
0 · Reply
Z_interceptor
Z_interceptor Jun. 26 at 8:44 AM
$ALLR - what a run !
1 · Reply
biotrade123
biotrade123 Jun. 25 at 5:24 PM
$ALLR all retail hoping this is the down before the pop up??
1 · Reply
BetterDayzz
BetterDayzz Jun. 25 at 8:45 AM
$ALLR It’s going to be a green summer for us. How high can it go? ✈️
0 · Reply
biotrade123
biotrade123 Jun. 24 at 1:36 PM
$ALLR could tank monday morning should the dilution vote pass??
0 · Reply
Latest News on ALLR
Allarity receives notice of allowance from USPTO

2026-04-27T13:21:02.000Z - 2 months ago

Allarity receives notice of allowance from USPTO


Allarity closes $20M financing for stenoparib advancement

2026-03-06T13:19:41.000Z - 4 months ago

Allarity closes $20M financing for stenoparib advancement


Allarity doses first patients in Phase 2 trial of SCLC

2026-02-18T13:25:56.000Z - 4 months ago

Allarity doses first patients in Phase 2 trial of SCLC


Allarity CEO says 2026 represents an ‘inflection point’

2025-12-31T13:05:34.000Z - 6 months ago

Allarity CEO says 2026 represents an ‘inflection point’


Allarity files $50M mixed securities shelf

2025-12-03T14:15:27.000Z - 7 months ago

Allarity files $50M mixed securities shelf


Allarity reports Q3 EPS (19c) vs ($7.71) last year

2025-11-14T14:06:08.000Z - 8 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year


Allarity files to sell 1.56M shares of common stock for holders

2025-09-25T21:25:29.000Z - 9 months ago

Allarity files to sell 1.56M shares of common stock for holders


Allarity presents new Phase 2 clinical data for Stenoparib

2025-09-22T12:20:54.000Z - 10 months ago

Allarity presents new Phase 2 clinical data for Stenoparib


Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-27T01:00:00.000Z - 10 months ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?


Allarity initiated with a Buy at Ascendiant

2025-07-28T09:50:42.000Z - 1 year ago

Allarity initiated with a Buy at Ascendiant


Allarity appoints Jeff Ervin as CFO

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO


Allarity Therapeutics Announces Changes to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors


Allarity announces research collaboration with IBRI

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI


biotrade123
biotrade123 Jun. 29 at 7:23 PM
$ALLR apparently the proposal to dilute was passed, Google AI bottomline: The Bottom Line The shareholder meeting confirms that ALLR is a trading utility, not a long-term fundamental investment. The institutional machinery is now fully authorized to keep the company listed and alive, using retail liquidity as its primary capitalization engine. The smart strategy here is to avoid getting caught up in retail board hype during a PR pump—instead, treat the $1.15 to $1.25 zone as a high-probability accumulation bounce pocket, and ruthlessly lock in profits anywhere near $1.55 to $1.70 before the automated Tumim dilution machine can grind the momentum back down.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 5:03 PM
$SLS sold 1K shares to buy more $ALLR $CGTX and $TNXP 🏦 💊 🧠 💤
2 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 3:56 PM
$KPTI lol Ipsen bought Kartos and not Karyopharm? How come CEO Richard Paulson and Karyopharm’s BD team couldn’t get that deal? Uncle Rolli and I could tell you why… we are focused on fixing biotechs, not just selling them on the cheap because private companies are often more poorly run than publicly traded ones. 🏦 $SLS $CCCC and $ALLR ALL DAY over the Krazy Pharm of Newton Massachusetts 😂
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 29 at 1:17 PM
$ALLR https://www.biospace.com/drug-development/4-ovarian-cancer-candidates-to-watch-gsk-allarity-and-more
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 27 at 5:22 AM
$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔
0 · Reply
Wody
Wody Jun. 26 at 7:27 PM
$ALLR how big is the drop gonna be AH and Monday?! Hope we start heading the other direction…
0 · Reply
Z_interceptor
Z_interceptor Jun. 26 at 8:44 AM
$ALLR - what a run !
1 · Reply
biotrade123
biotrade123 Jun. 25 at 5:24 PM
$ALLR all retail hoping this is the down before the pop up??
1 · Reply
BetterDayzz
BetterDayzz Jun. 25 at 8:45 AM
$ALLR It’s going to be a green summer for us. How high can it go? ✈️
0 · Reply
biotrade123
biotrade123 Jun. 24 at 1:36 PM
$ALLR could tank monday morning should the dilution vote pass??
0 · Reply
The_Stock_Nazgul
The_Stock_Nazgul Jun. 23 at 8:31 PM
$ALLR Anyone knows what happens if proposal 7 (the one allowing them to postpone the meeting to get more votes by proxy) doesn't pass? Because how do we know if they intend to cheat us? They literally did this like 2 years ago
2 · Reply
Wody
Wody Jun. 23 at 1:46 PM
$ALLR tick tock
0 · Reply
Unalloyed
Unalloyed Jun. 23 at 12:01 PM
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 22 at 7:20 PM
$ALLR buying opportunities all over 👍 $PHVS is interesting 💊 $GH too 📊 Sold my $FBIO shares to buy other things 🏦 GLBB ☘️ 🐂
1 · Reply
biotrade123
biotrade123 Jun. 22 at 1:33 PM
$ALLR closing red today🤞🤞
1 · Reply
Jimesica
Jimesica Jun. 22 at 1:17 PM
$ALLR ESMO Poster: “As a Trial-in-Progress presentation, the poster describes the study design and clinical rationale but cannot include new clinical data.” “For Allarity, this is an important opportunity to highlight the clinical rationale and design of our stenoparib study, while beginning to frame the potential role our drug-specific DRP® patient selection approach may play in addressing advanced platinum-resistant or platinum-ineligible ovarian cancer for this highly specialized audience. https://allarity.com/wp-content/uploads/2026/06/A-phase-2-trial-of-stenoparib2X-121-a-novel-dual-inhibitor-of-PARP-and-the-WNT-pathway.pdf
0 · Reply
focafoca99
focafoca99 Jun. 22 at 12:27 PM
$ALLR presented a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 22 at 12:09 PM
$ALLR looking good 💊
1 · Reply
Popsiclestick
Popsiclestick Jun. 22 at 2:08 AM
0 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 21 at 4:26 PM
$ALLR Daily Chart Update: Defense at 200 day SMA & Bullish Trading Range Reversal Shifting to the daily, price action shows a high probability reversal of the recent daily range taking shape inside its macro weekly trading range. Most trading range breakouts fail. The bears’ recent attempt to breakdown out of the daily range was rejected. Price tested the lower boundary & 200 day SMA area of value Wednesday & Thursday, forming a micro double bottom. This was confirmed with an expansion of volume & powerful “outside up” bull trend bar. A clean move above $1.48 signals that buyers have regained control, creating a high probability for 1 to 2 legs up toward the upper boundary. As market awareness grows around the upcoming P2 data catalyst, this internal daily momentum sets the technical stage for an eventual breakout of the range to test the major resistance at $2.35 in the coming weeks.
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 21 at 3:40 PM
$ALLR Multi Year Stage 1 Base Nearing Transition into Stage 2 Advance: The stock has put in a solid ~2 year base, with a clear structural shift between the left and right sides of the pattern following the 8/26 FAST track designation. Since the February lows, the market has transitioned into a "Spike and Small Pullback Bull Channel," with a higher frequency of large bull trend bars closing near their highs, a clear sign of accumulation. Price cleared its rising 10 & 30 week SMAs. Buyers aggressively bought last weeks test of the 30 SMA forming a big lower tail, closing price back toward the 10 SMA. The macro gatekeeper sits at horizontal resistance around $2.35. A strong weekly close above this level & with follow through triggers a Stage 2 breakout. Given the tight capital structure of 16M shares, a breakout past this ceiling leaves very little overhead resistance, paving the way for a quick move to the $4.00–$5.00 liquidity pocket and potentially higher.
1 · Reply
sixmilliondollarman
sixmilliondollarman Jun. 21 at 3:37 PM
$ALLR AI assessment of Madstockalerts nonsense is just more nonsense. I’ll post our assessment 👆
0 · Reply